ArticleWorld journal of clinical oncology2025
Diagnosis and treatment of metachronous multiple primary carcinoma: A case report and review of literature.
Article in World journal of clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMultiple primary carcinoma (MPC) refers to two or more types of primary malignant tumors occurring simultaneously or sequentially in the same patient. Breast cancer is one of the most common malignant tumors affecting women. On the other hand, diffuse large B-cell lymphoma (DLBCL) is the most frequent form of non-Hodgkin's lymphoma (NHL). In clinical practice, the simultaneous existence of metachronous primary breast cancer and lymphoma is rare. In this case, we highlight the significance of multidisciplinary management and advanced imaging techniques in the early identification and treatment of MPC cases. CASE SUMMARY: In this study, we report a case of a 40-year-old female who was diagnosed with invasive ductal carcinoma of the breast (T3N1M0 stage IIIA LuminalB type) as the first primary cancer and DLBCL (stage IIIA) as the second primary cancer. The patient underwent the modified radical mastectomy for left breast cancer and received Rituximab, cyclophospha-mide, hydroxydaunorubicin, Oncovin (vincristine) and prednisolone regimen chemotherapy treatment for DLBCL. As of now, the patient is in stable condition. The successful diagnosis of the present patient highlights the need for multidisciplinary management and adoption of advanced imaging techniques to identify the second primary cancer, especially NHL.
conclusionAccurate diagnosis and management of metachronous MPC requires an interdisciplinary team and selection of an appropriate treatment plan.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.